Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. This therapy has shown remarkable results with hematological malignancies (including anti-CD19 CAR T therapy against B-cell malignancies).  To help accelerate research in this field, we provide a comprehensive platform of in vitro services and in vivo animal models for supporting project teams focused on the discovery of CAR T-cell therapies.

In vitro Assays and Services

• CAR design and construction (sequence optimization, lentiviral vector selection)
• Packaging of viral particles (titration, viral copy number)
• Optimization of transfection efficiency of CAR T-cells with lentiviral transduction enhancers
• Functional evaluation, including cytotoxicity testing (co-culturing CAR T-cells and tumor cells) and measurements of cytokine release
• Optimization of culture media and conditions for CAR T-cell proliferation
• Analysis of CAR expression via flow cytometry
• Expansion of CAR T-cells and phenotype characterization (differentiation of T-cells)
• Biomarker services (multiplexed tissue staining)
• Safety QC assessment (endotoxin, mycoplasma)

• Tumor volume measurements (for subcutaneous models)
• Bioluminescence imaging (for systemic and orthotopic models)
• Survival analysis
• Clinical observations (including necropsy at endpoint)
• Infiltration of CAR T-cells in tumor and tissue
• Proliferation, survival, and long-term persistence of CAR T-cells
• T cell phenotype analysis (e.g., memory and effector T-cells, Tregs)
• Toxicity assessment (including single-dose toxicity and cytokine release)